Have a Claim?

Click here for a confidential contact or call:


July 29, 2022

Posted  July 29, 2022

Allergan will pay up to $2.27 billion to settle allegations they deceptively marketed opioids by downplaying the risks of opioid addiction and instead touting exaggerated benefits from the drugs. Rather than encouraging alternative treatments, Allergan encouraged doctors to prescribe more opioids, and failed to maintain effective controls to prevent diversion of opioids. This settlement involves multiple states, excluding New York, which settled separately with Allergan. VA OAG

Tagged in: Healthcare Fraud, Off-Label and Unapproved Use, Pharma Fraud,